Belviq XR lorcaserin extended release regulatory update

Eisai and Arena said FDA approved an NDA for once-daily Belviq XR lorcaserin extended release for chronic weight management. The companies expect the drug to be available this fall. The approval triggered a $10 million milestone payment to Arena under a deal granting Eisai exclusive rights to commercialize the product worldwide, excluding Australia, Israel, New Zealand, South Korea and Taiwan (see BioCentury, July 5, 2010; Aug. 6, 2012 & Nov. 11, 2013). ...